Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

COS and Genesis Research

Genesis Research and Clinical Outcomes Solutions announce innovative partnership

International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...

Genesis Research Group

- PMLiVE

NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia

The treatment will be funded and available for use within 90 days in the NHS

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

Around 2,800 breast cancer patients in England and Wales could benefit from the treatment

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

- PMLiVE

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

The recommendation will give those living with the condition in England and Wales access to a new treatment option

- PMLiVE

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year

- PMLiVE

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Eligible patients will now be able to access the treatment through the NHS in England

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links